Heparin Reversal / Cardiac Surgery
Pregnancy: Use only if essential — limited data; short-term procedural use in peripartum cardiac surgery
Protamine Sulphate (Heparin Reversal)
Brand names: Protamine Sulphate 1%
Adult dose
Dose: 1 mg protamine neutralises approximately 80-100 units UFH. Post-cardiopulmonary bypass: 1 mg per 100 units heparin given in past 2-3 hours. IV slow injection over 10 minutes. Maximum 50 mg per injection.
Route: Intravenous slow injection over 10 minutes
Frequency: Single dose or repeated as per ACT monitoring
Max: 50 mg per single dose
Positively charged protein — binds negatively charged heparin to form inactive complex. Widely used after cardiac surgery (post-bypass reversal). Check ACT after administration. Excess protamine has anticoagulant effect — do NOT overdose.
Paediatric dose
Route: IV slow injection
Frequency: Per protocol
Max: 1 mg per 100 units UFH
Same weight-based calculation as adults. Specialist paediatric cardiac surgery only. Slow injection critical — adverse reactions more common with rapid administration.
Dose adjustments
Renal
No dose adjustment required
Hepatic
No dose adjustment required
Clinical pearls
- NPH insulin allergy risk: NPH (neutral protamine Hagedorn) insulin contains protamine as a carrier protein. Patients on NPH insulin have ~50-fold higher risk of protamine allergy. Warn anaesthesia team pre-cardiac surgery if patient uses NPH insulin. Consider using insulin analogues (glargine, detemir) perioperatively.
- Excess protamine anticoagulation: paradoxically, too much protamine has anticoagulant effects (inhibits platelet aggregation and thrombin activity). ACT monitoring guides dosing — target ACT returning to baseline (pre-heparin). Do not redose blindly.
- LMWH reversal: protamine reverses anti-IIa activity of LMWH completely but only ~60% of anti-Xa activity. For enoxaparin: 1 mg protamine per 1 mg enoxaparin (if within 8h); 0.5 mg protamine per 1 mg enoxaparin (if 8-12h). A second dose may be needed.
- Heparin rebound: after cardiac surgery, heparin sequestered in tissues may be released hours after protamine administration — 'heparin rebound' causes recurrent anticoagulation. Monitor ACT for 4-6 hours post-reversal. Second protamine dose may be required.
- Slow injection mandatory: rapid IV protamine causes histamine release, complement activation, and severe hypotension. Always inject over 10 minutes. Premedication with antihistamine considered in high-risk patients (NPH insulin, fish allergy).
Contraindications
- Hypersensitivity to protamine
- NPH insulin-dependent diabetics or previous protamine exposure (higher allergy risk)
- Fish allergy (protamine derived from fish sperm — cross-reactivity possible)
Side effects
- Hypotension (most common — rate-related; give slowly over 10 minutes)
- Bradycardia
- Anaphylaxis/anaphylactoid reactions (higher risk in NPH insulin users, previous protamine exposure, fish allergy)
- Pulmonary hypertension (mechanism unclear — complement activation)
- Paradoxical anticoagulation (excess protamine — anticoagulant effect)
- Nausea
Interactions
- Heparin — pharmacological antagonism (therapeutic interaction — reversal)
- LMWH — partially reversed by protamine (protamine neutralises anti-IIa but NOT anti-Xa activity of LMWH; only ~60% reversal)
Monitoring
- ACT (activated clotting time — before and after protamine)
- Blood pressure during infusion
- Signs of allergic reaction
- Haemostasis assessment post-bypass
Reference: BNFc; BNF 90; BNFc; Cardiothoracic Anaesthesia Society Guidelines; AAGBI Guidelines; SPC Protamine Sulphate 1%. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- ASA Physical Status Classification · Pre-operative Risk
- Train-of-Four (TOF) Neuromuscular Monitoring · Neuromuscular Blockade
- Revised Cardiac Risk Index (RCRI / Lee Index) · Perioperative Risk
- Cardiac Output (Fick Method) · Haemodynamics
- Revised Cardiac Risk Index (RCRI) · Pre-operative Risk
- Duke Activity Status Index (DASI) · Functional Assessment
Pathways
- Acute Heart Failure · ESC 2021 Heart Failure Guidelines; NICE NG106
- NSTEMI / Unstable Angina · ESC 2020 NSTEMI Guidelines; NICE NG185
- New-Onset Atrial Fibrillation · ESC 2020 AF Guidelines; NICE NG196
- Hypertensive Emergency · ESC/ESH 2018 Hypertension Guidelines; NICE NG136
- Bradycardia Management · Resuscitation Council UK ABCDE; ESC 2021 Pacing Guidelines
- Ventricular Tachycardia / Fibrillation · Resuscitation Council UK ACLS; ESC 2022 Ventricular Arrhythmia Guidelines